Search

everythinglearnresearchcommunity

for

Search:↓

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Autoimmune and inflammatory processes are involved in both scarring and non-scarring types of hair loss.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

Current and future treatments for alopecia areata focus on immunosuppression, immunomodulation, and protecting hair follicles.

Granulomatous Alopecia Areata is rare and may be caused by hair antigens or follicle destruction.

Gut bacteria differences could help diagnose and treat alopecia areata.

A 6-year-old boy's skin condition improved after stopping a specific treatment and starting new medications.

Some autistic children may have higher levels of male hormones, which could be linked to aggression.

A woman's rare hair loss condition improved on its own, suggesting this type might recover like common cases.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.

Children with frequent severe infections and low antibodies should be checked for immune deficiencies.

CT60 polymorphism might increase the risk of Alopecia Areata.

An 11-year-old child with total hair loss may have a genetic autoimmune disease, and the outlook for hair regrowth is not good.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

The skin plays a key role in immune responses and reflects emotional and stress reactions.

Dupilumab can help hair regrowth but may also trigger alopecia areata.

Some people with alopecia areata, a hair loss condition, get better within a year without treatment, but it can happen again.

Mast cells and the CB1 receptor may be key in causing IgA vasculitis.

Early diagnosis and treatment of achalasia and hyperthyroidism improve patient outcomes.

MDSC-Exo can treat autoimmune alopecia areata and promote hair regrowth in mice.

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

Some patients with Alopecia Areata experience itch due to immune cells and enzymes that cause itching.

Hair loss involves immune responses, inflammation, and disrupted signaling pathways.

Some hair growth cells remain in partially bald areas of Indian men with hair loss.

Topical immunomodulators are effective and safe for treating immune-related skin conditions.

Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.

SOCS3 treatment can prevent hair loss by stopping harmful immune responses.

AI improves biomaterial design by making it faster, cheaper, and more effective for personalized medicine.